Akeso, Inc. announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and...
Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation...
Regeneron Pharmaceuticals, Inc and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
COVID-19 has irrevocably changed the landscape of the healthcare industry. The rapid digitalization of this industry has demonstrated that we as consumers have quickly...
